In our early experimental (with W-256, SM-1 and PC-1
tumors) and clinical (breast, bladder and
prostate cancers) studies the use of the anticancer
drug NSC-631570 was proven to be safe and highly effective, inhibiting
protein synthesis in
cancer cells, selectively accumulating in
cancer tissue after a single
intravenous administration and controlling
cancer-induced metabolic imbalance. This
drug inhibits metabolic processes in the
tumor and causes metabolic disorders in
cancer cells. Moreover,
NSC-631570 induced the changes in certain
amino acids concentrations in
biological fluids and
tumor tissue in animal models and
cancer patients. These changes cannot be explained by metabolic
amino acid disorders in
cancer known so far. In this study the effects of
NSC-631570 on blood plasma
amino acids has been investigated. Blood was sampled from 10 healthy donors and 29 patients with different types of
cancer (stomach, rectal, lung, breast, bladder, prostate, and
leukemia). Comparison of NSC-531570 effects in plasma of healthy donors and
cancer patients has shown, that this compoumd: 1) affects
amino acids with positively charged (His, Arg) or not charged (Tyr, Thr, Gln) R-groups; 2) decreases concentration of His and increase the concentrations of beta-Ala and Tau. These changes depend on the concentration of
NSC-631570 and the type of
cancer. On the basis of the literature data and the results of our studies we suggest that
Ukrain's
biological actions in
cancer are realized at least partly through selective interaction with
amino acids, their derivatives, and
plasma proteins. These data provide the background for the using
Ukrain in the
cancer detection and investigating the mechanisms of
carcinogenesis.